Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes
Top Cited Papers
Open Access
- 7 April 2020
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 105 (2), 216-221
- https://doi.org/10.1136/bjophthalmol-2020-315933
Abstract
Background/AimTo assess visual acuity (VA) outcomes and antivascular endothelial growth factor (anti-VEGF) treatment intensity in diabetic macular oedema (DMO).MethodsRetrospective analysis was performed in treatment-naïve patients with DMO from 2013 to 2018 using a database of aggregated de-identified electronic medical records (Vestrum Health).ResultsAt 1 year, 28 658 patient eyes underwent a mean of 6.4 anti-VEGF injections, gaining a mean of +4.2 letters (95% confidence interval for mean gain: +4.0 to +4.5 letters, pConclusionIn clinical practice, patients with DMO undergo fewer anti-VEGF injections and exhibit worse visual gains compared with patients in randomised clinical trials. Visual outcomes correlate with treatment intensity at 1 year, with ceiling effects related to baseline VA.Keywords
This publication has 21 references indexed in Scilit:
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaThe New England Journal of Medicine, 2015
- Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edemaClinical Ophthalmology, 2014
- Intravitreal Aflibercept for Diabetic Macular EdemaOphthalmology, 2014
- Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGFExpert Review of Clinical Pharmacology, 2014
- Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in HumansAmerican Journal of Ophthalmology, 2012
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)Retina, 2011
- What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical modelEye Reports, 2011
- IntroductionPublished by Springer Science and Business Media LLC ,2011
- NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTSRetina, 2010